[3-(methoxymethoxy)-5-methylphenyl]methanol | 186018-63-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: [3-(methoxymethoxy)-5-methylphenyl]methanol
• CAS: 186018-63-3
• 化学式: C₁₀H₁₄O₃
• 分子量: 182.219
• InChiKey: SHRPDQIUQLPOIC-UHFFFAOYSA-N

物化性质

• 沸点：
  311.2±37.0 °C(Predicted)
• 密度：
  1.095±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  [3-(methoxymethoxy)-5-methylphenyl]methanol 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 正丁基锂 、 三乙胺 、 cesium fluoride 作用下， 以 四氢呋喃 、 乙醚 、 乙醇 、 正己烷 、 水 为溶剂， 反应 68.5h， 生成 (2S,3S)-2-[[3-[2-(hydroxymethyl)-6-(methoxymethoxy)-4-methylphenyl]-8-(methoxymethoxy)-1,4-dioxonaphthalen-2-yl]amino]-3-methylpentanoic acid
  参考文献：
  名称：

  Synthesis of jadomycin A and related jadomycin aglycons: structural re-examination of jadomycins S and T may be needed

  摘要：

  Jadomycin A and related jadomycin M and W aglycons were synthesized. Easy re-construction of 4(hydroxymethyl)-1,3-oxazolidin-5-one system into an isomeric 1,3-oxazolidine-4-carboxylic acid system during the synthetic trial of jadomycin S aglycon requests us to more precisely re-examine the structures proposed for jadomycins S and T, derived from hydroxyl-containing amino acids of L-serine and L-threonine, respectively. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2011.10.160
• 作为产物：
  描述：

  3-羟基-5-甲基苯甲酸 在 lithium aluminium tetrahydride 、 硫酸 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 37.0h， 生成 [3-(methoxymethoxy)-5-methylphenyl]methanol
  参考文献：
  名称：

  Syntheses of fenanthroviridone, gilvocarcin BE-12406X2, and antibiotic ws 5995b based on the palladium and copper catalyzed coupling of organostannanes with bromoquinones

  摘要：

  A total synthesis of fenanthroviridone, gilvocarcin BE-12406X(2) antibiotic WS 5995B is described based on the palladium and copper catalyzed coupling reaction of sterically hindered aryl stannanes with a 2-bromonaphthoquinone. Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/s0040-4039(96)02056-4

文献信息

• Fused Phenyl Amido Heterocyclic Compounds
  申请人：Bai Hao

  公开号：US20110039821A1

  公开（公告）日：2011-02-17

  The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt or solvate thereof, wherein: Ring A is (4-12)-membered heterocyclyl; Ring B is a fused benzene ring selected from the group consisting of: Ring A, ring B, ring C, R 1 , R 1a , R 2 , R 3 , R 4 , L 2 , n, t, w, and z are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of glucokinase, the method comprising administering to a mammal an effective amount of a compound of formula (I).

  本发明涉及以下式子的化合物(I)或其药学上可接受的盐或溶剂： 其中，环A是(4-12)成员杂环基；环B是从以下组中选择的融合苯环：环A、环B、环C、R1、R1a、R2、R3、R4、L2、n、t、w和z在规范中定义。本发明还涉及包括式(I)化合物的药物组合物和通过调节葡萄糖激酶介导的疾病的治疗方法，该方法包括向哺乳动物施用式(I)化合物的有效量。
• FURAN OR THIOPHENE DERIVATIVE AND MEDICINAL USE THEREOF
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1535915A1

  公开（公告）日：2005-06-01

  The present invention provides a compound represented by the formula (I): [wherein R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, p is 0, 1 or 2, and when p is 2, each R may be the same or different, R1 is a hydrogen atom or an optionally substituted hydrocarbon group, R2 is an optionally substituted aromatic group, Ring A is an optionally substituted monocyclic aromatic ring or optionally substituted bicyclic aromatic fused ring, X1 is an oxygen atom or a sulfur atom, X2 is a bond, an oxygen atom or -S(O)n- (wherein n is 0, 1 or 2), Y is a bond, an oxygen atom, -S(O)m-, -C(=O)-N(R3)- or -N(R3)-C(=O)- (R3 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and m is 0, 1 or 2), M1, M2 and M3 may be the same or different and are each independently a bond or an optionally substituted divalent aliphatic hydrocarbon group, and M4 is an optionally substituted divalent aliphatic hydrocarbon group] or a salt thereof, which is useful as a prophylactic and/or therapeutic agent for lipid metabolism abnormality, arteriosclerotic disease and sequelae thereof, diabetes mellitus and the like.

  本发明提供了一种由式（I）表示的化合物： [其中 R 为任选取代的烃基或任选取代的杂环基，p 为 0、1 或 2，当 p 为 2 时，每个 R 可以相同或不同，R1 为氢原子或任选取代的烃基，R2 为任选取代的芳香基、环 A 是任选取代的单环芳香环或任选取代的双环芳香融合环，X1 是氧原子或硫原子，X2 是键、氧原子或 -S(O)n- （其中 n 是 0、1 或 2），Y 是键、氧原子、-S(O)m-、-R3是氢原子、任选取代的烃基或任选取代的杂环基，m是0、1或2），M1、M2和M3可以相同或不同，各自独立地是键或任选取代的二价脂族烃基、和 M4 是任选取代的二价脂族烃基]或其盐，可用作脂质代谢异常、动脉硬化疾病及其后遗症、糖尿病等的预防和/或治疗剂。
• Furan or thiopene derivative and medicinal use thereof
  申请人：Hamamura Kazumasa

  公开号：US20060100261A1

  公开（公告）日：2006-05-11

  The present invention provides a compound represented by the formula (I): [wherein R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, p is 0, 1 or 2, and when p is 2, each R may be the same or different, R 1 is a hydrogen atom or an optionally substituted hydrocarbon group, R 2 is an optionally substituted aromatic group, Ring A is an optionally substituted monocyclic aromatic ring or optionally substituted bicyclic aromatic fused ring, X 1 is an oxygen atom or a sulfur atom, X 2 is a bond, an oxygen atom or —S(O) n — (wherein n is 0, 1 or 2), Y is a bond, an oxygen atom, —S(O) m —, —C(═O)—N(R 3 )— or —N(R 3 )—C(═O)— (R 3 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and m is 0, 1 or 2), M 1 , M 2 and M 3 may be the same or different and are each independently a bond or an optionally substituted divalent aliphatic hydrocarbon group, and M 4 is an optionally substituted divalent aliphatic hydrocarbon group] or a salt thereof, which is useful as a prophylactic and/or therapeutic agent for lipid metabolism abnormality, arteriosclerotic disease and sequelae thereof, diabetes mellitus and the like.

  本发明提供了一种由式（I）表示的化合物： [其中 R 为任选取代的烃基或任选取代的杂环基，p 为 0、1 或 2，当 p 为 2 时，每个 R 可以相同或不同，R 1 是氢原子或任选取代的烃基，R 2 是任选取代的芳香基团，环 A 是任选取代的单环芳香环或任选取代的双环芳香融合环，X 1 是氧原子或硫原子，X 2 是键、氧原子或 -S(O) n - 其中 n 为 0、1 或 2），Y 为键、氧原子、-S(O) m -、-C(═O)-N(R 3 )-或-N(R 3 )-C(═O)-(R 3 是氢原子、任选取代的烃基或任选取代的杂环基，且 m 是 0、1 或 2），M 1 , M 2 和 M 3 可以相同或不同，且各自独立地为键或任选取代的二价脂族烃基，以及 M 4 是任选取代的二价脂族烃基]或其盐，可用作脂质代谢异常、动脉硬化疾病及其后遗症、糖尿病等的预防和/或治疗剂。
• EP1535915
  申请人：——

  公开号：——

  公开（公告）日：——
• US7553867B2
  申请人：——

  公开号：US7553867B2

  公开（公告）日：2009-06-30